But as more Americans gain access to cheaper weight-loss medication, food executives are increasingly minding those who are minding their waists
Structure Therapeutics announces initiation of phase 1 clinical study of oral small molecule amylin receptor agonist ACCG-2671 for the treatment of obesity
Many patients report better tolerance when they dose in the evening after a light meal rather than on an empty stomach
Daniel Bessesen, chief of endocrinology at Denver Health, who treats patients with obesity but was not involved in the new research
The losses are very material, said Mike Guerriere, chief actuary for Blue Cross Blue Shield of Massachusetts, in an interview
(PubMed) Caldwell KL, Makhmudov A, Ely E, Jones RL, Wang RY